Document is current
Any future updates will be listed below
-
Authors
Roberti, Domenico https://orcid.org/0000-0003-0948-3910
Grier, Abby L. https://orcid.org/0000-0002-5199-8670
Reisz, Julie A. https://orcid.org/0000-0002-7296-4963
Vallefuoco, Fara
Key, Alicia https://orcid.org/0000-0002-8787-8144
Bevers, Shaun https://orcid.org/0000-0002-2000-6106
Dzieciatkowska, Monika https://orcid.org/0000-0002-9947-2520
Nemkov, Travis
Contieri, Marcella
Zanfardino, Angela
Norris, Philip J.
Busch, Michael P. https://orcid.org/0000-0002-1446-125X
Kauffman, Vienna
Morton, Holmes D.
Earley, Eric J.
Page, Grier P.
Marzuillo, Pierluigi https://orcid.org/0000-0003-4682-0170
D’Alessandro, Angelo https://orcid.org/0000-0002-2258-6490
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R21HL150032, R01HL146442, R01HL148151, R01HL149714)
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 11 July 2025
First Online: 26 July 2025
Competing interests
: A.D. and T.N. are founders of Omix Technologies and advisory board members of Hemanext Inc. A.D. is also a SAB member for Macopharma. D.R. received consulting fees from Nerviano Medical Sciences S.r.l. and Agios Pharmaceuticals, Inc., unrelated to the topic described and the research performed for the manuscript. The other authors have no conflicts to disclose.
